A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis
Open accessThe DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index; 12 of the 30 sources its claims cite were checked for support.
Abstract
Phase 3 placebo-controlled trial of obeticholic acid in patients with PBC who had inadequate response to or unacceptable side effects with UDCA.
Overview
CoChat Summary
TL;DR
In the 12-month POISE phase 3 trial, obeticholic acid added to ursodiol or given as monotherapy improved the composite biochemical primary end point in patients with primary biliary cholangitis compared with placebo. Obeticholic acid also increased pruritus and serious adverse events.
Key findings
- The primary composite end point occurred in 46% of the 5–10-mg group and 47% of the 10-mg group versus 10% of the placebo group (P<0.001 for both comparisons).
- Alkaline phosphatase decreased by least-squares mean −113 U/L in the 5–10-mg group and −130 U/L in the 10-mg group versus −14 U/L with placebo (P<0.001 for both); total bilirubin changed by −0.02 and −0.05 mg/dL versus +0.12 mg/dL, respectively (P<0.001 for both).
- Noninvasive measures of liver fibrosis did not differ significantly between either obeticholic acid group and placebo at 12 months.
- Pruritus occurred in 56% of the 5–10-mg group and 68% of the 10-mg group versus 38% with placebo; serious adverse events occurred in 16%, 11%, and 4%, respectively.
Methods
- Randomized, double-blind, placebo-controlled, parallel-group, 12-month phase 3 trial at 59 sites in 13 countries; 217 patients underwent randomization and 216 received at least one dose, assigned 1:1:1 to placebo, obeticholic acid 5 mg with adjustment to 10 mg if applicable, or obeticholic acid 10 mg.
- Patients had primary biliary cholangitis with inadequate response to ursodiol or unacceptable ursodiol side effects; 93% received ursodiol as background therapy.
- Primary end point: alkaline phosphatase <1.67× upper limit of normal with ≥15% reduction from baseline and normal total bilirubin at 12 months; analyzed in the intention-to-treat population with Cochran–Mantel–Haenszel testing stratified by randomization factors, with missing values counted as nonresponse.
Limitations
- The paper states that results cover only 2 years of treatment, that the trial focused on surrogate biomarkers, imaging, and symptom end points with no statistical power to assess clinical outcomes, and that multiplicity adjustments were made only for the primary end point and not for secondary or exploratory analyses.
- Evident from the text: the open-label extension was not placebo-controlled, so longer-term durability and crossover findings are uncontrolled.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
10 Valid · 1 Not valid · 12 Not checked · 78 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“In addition, FXR regulates other pathways with direct antiinflammatory and antifibrotic effects. 13-15”
What the sources say
- Not checked — no full text of the sourcecites [13] source
- Disputedcites [14] sourceExperimental — accuracy not yet measured
The Discussion’s Systematic review says FXR agonists have indirect anti-fibrotic effects in animal models, contrary to the claim of direct anti-fibrotic effects. The cited passages do not describe direct anti-inflammatory effects or identify such pathways; page numbers are unavailable in our copy. (LLM, conf=0.84)
Checked by a reasoning model — may be wrong.
- Not checked — no full text of the sourcecites [15] source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In two 12-week phase 2 studies, daily doses of up to 50 mg of obeticholic acid resulted in reductions from baseline in levels of alkaline phosphatase and bilirubin that were significantly greater than those with placebo. 16”
What the sources say
- Partly supportedcites [16] sourceExperimental — accuracy not yet measured
The Abstract and Primary Efficacy End Point section report one three-month placebo-controlled trial in which daily obeticholic acid doses of 10–50 mg significantly reduced alkaline phosphatase versus placebo. The Secondary End Points section reports lower median conjugated bilirubin with obeticholic acid, but does not state that this reduction was statistically significant versus placebo. This paper therefore does not support the claim about two studies or the stated significance for bilirubin. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“However, dose-related increases in the incidence and severity of pruritus were evident, particularly at doses of more than 10 mg.”
What the sources say
- Supportedcites [16] source
The Adverse Events section says both pruritus incidence and severity were worse in the 25-mg and 50-mg groups than at 10 mg. It reports severe pruritus in 16%, 24%, and 37% of patients at 10, 25, and 50 mg, respectively. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In a large, international cohort analysis involving patients with primary biliary cholangitis, elevations in the alkaline phosphatase level were independently associated with a risk of liver transplantation or death that was 2.0 to 2.5 times as high as the risk associated with normal levels. 10”
What the sources say
- Partly supportedcites [10] sourceExperimental — accuracy not yet measured
The Statistical Analysis section (p. 3) says the analyses adjusted for age, sex, year of diagnosis, and UDCA therapy. The Results (p. 4) find higher alkaline phosphatase associated with greater risk of transplantation or death, but compare patients above 2.0 times the upper limit of normal with those at or below that threshold—not specifically with patients whose alkaline phosphatase was normal. The cited passages do not establish the claimed 2.0-to-2.5-fold risk relative to normal levels. (LLM, conf=0.86)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Among the subgroup of patients who had transient elastography assessed (43%), obeticholic acid was not associated with significant reductions in this noninvasive measure of liver fibrosis at 12 months.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
45 more claims
Create a free account to see all 101 claims and every source verdict.
- Probably not a substantial claim. 22
- It may state two separate claims as one. 39
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Serum ALP dropped by 53.9% in the 10-mg group, 37.2% in the 50-mg group, and by only 0.8% in the placebo group.(160)”
From Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases (2019) · cites this paper as [160]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Again, pruritus was the most important adverse event, leading to discontinuation of 38% of study subjects in the 50-mg arm.”
From Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases (2019) · cites this paper as [160]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In an intention-to-treat analysis, biochemical response was met in 10% of the placebo group relative to 47% and 46% in the 10 mg and 5-10 mg dose-titrated OCA groups, respectively (p \0.0001 for both).”
From EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. (2017) · cites this paper as [131]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Fatigue is not related to severity of liver disease, with the exception of very end-stage patients where it is the norm [221], and it is not responsive to UDCA or OCA therapy [6,131].”
From EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. (2017) · cites this paper as [131]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition, OCA was not effective in decreasing PBC-induced liver fibrosis21,22.”
From SUMOylation inhibitors synergize with FXR agonists in combating liver fibrosis (2020) · cites this paper as [21]
Experimental — accuracy not yet measured
44 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Neuschwander-Tetri, B. A., Loomba, R., Sanyal, A. J., Lavine, J. E., Van Natta, M. L., Abdelmalek, M. F., Chalasani, N., Dasarathy, S., Diehl, A. M., Hameed, B., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61933-4 · Cited by 2,237
Self-citationEASL Clinical Practice Guidelines: management of cholestatic liver diseases
European Association for the Study of the Liver (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.04.009 · Cited by 1,729
Role of Bile Acids and Bile Acid Receptors in Metabolic Regulation
Lefebvre, P., Cariou, B., Lien, F., Kuipers, F., & Staels, B. (2009) · Physiological Reviews · doi:10.1152/physrev.00010.2008 · Cited by 1,678
Targeting bile‐acid signalling for metabolic diseases
Thomas, C., Pellicciari, R., Pruzanski, M., Auwerx, J., & Schoonjans, K. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2619 · Cited by 1,422
Self-citation(2011) · Encyclopedia of Cancer · doi:10.1007/978-3-642-16483-5_4730 · Cited by 1,240
Lindor, K. D., Gershwin, E. M., Poupon, R., Kaplan, M., Bergasa, N. V., & Heathcote, J. E. (2009) · Hepatology · doi:10.1002/hep.22906 · Cited by 1,099
Self-citationPellicciari, R., Fiorucci, S., Camaioni, E., Clerici, C., Costantino, G., Maloney, P. R., Morelli, A., Parks, D. J., & Willson, T. M. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm025529g · Cited by 743
Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis
Corpechot, C., Abenavoli, L., Rabahi, N., Chrétien, Y., Andréani, T., Johanet, C., Chazouillères, O., & Poupon, R. (2008) · Hepatology · doi:10.1002/hep.22428 · Cited by 646 · cited 3×
“(%) Death 1 (<1) Pruritus 4 (2) Other AEs 6 (3) Withdrew consent 5 (3) Other 4 (2) OLE = open-label extension a Denominator is based off the number randomized in each treatment group.”
BackgroundPrimary Biliary Cirrhosis Associated with HLA, IL12A, and IL12RB2 Variants
Hirschfield, G. M., Liu, X., Xu, C., Lu, Y., Xie, G., Lu, Y., Gu, X., Walker, E. J., Jing, K., Juran, B. D., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810440 · Cited by 594
Self-citationHirschfield, G. M., Mason, A., Luketic, V., Lindor, K., Gordon, S. C., Mayo, M., Kowdley, K. V., Vincent, C., Bodhenheimer, H. C., Parés, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2014.12.005 · Cited by 576
Self-citation
Research works printed but not linked: 1
- Bolier AR, 2012, Acta Gastroenterol Belg, 75, 399
Cited by
Items 801–900 of 1,138
Cançado, G. G. L., Chen, B., Cameron, M., Houri, I., Leung, K. K., Gulamhusein, A. F., Hansen, B. E., & Hirschfield, G. M. (2025) · Hepatology Communications · doi:10.1097/hc9.0000000000000798 · Cited by 7
“[20,23] By contrast, in a real-world study from the United Kingdom, the proportion of patients attaining complete normalization in serum ALT significantly increased over time under OCA therapy, but not following treatment with fibrates, when used as second-line drugs.”
Self-citationCurrent and future opportunities for the management of primary biliary cholangitis
Naffouj, S., & Wang, J. R. (2023) · Frontiers in Gastroenterology · doi:10.3389/fgstr.2023.1241901 · Cited by 5
“The medication was approved by the Food and Drug Administration (FDA) and European Medicines Agency (EMA) based on results of the POISE trial in 2016, showing its ef fi cacy in improving biochemical markers in high-risk subgroups (16).”
Primary biliary cholangitis: assessment and management strategies
Abbas, S. N., Jones, D. E., Kallis, Y. N., Maher, L., & Patanwala, I. (2021) · Gastrointestinal Nursing · doi:10.12968/gasn.2021.19.sup4.s1 · Cited by 3
Self-citationPhase 3 Trials of Elafibranor and Seladelpar for Primary Biliary Cholangitis
Kowdley, K. V., Levy, C., & Jones, D. (2024) · New England Journal of Medicine · doi:10.1056/nejmc2403986 · Cited by 3
Self-citationTreatment of Primary Biliary Cholangitis including Transplantation
Muzahim, Y., Wakil, A., Bassi, M., & Pyrsopoulos, N. (2023) · Clinics in Liver Disease · doi:10.1016/j.cld.2023.07.003 · Cited by 4
Review of pharmacotherapeutic treatments for primary sclerosing cholangitis
Zhang, C., Hussaini, T., & Yoshida, E. M. (2019) · Canadian Liver Journal · doi:10.3138/canlivj-2018-0016 · Cited by 3
Wu, Z., Shi, J., Zhang, Y., Shi, R., Guo, Q., Zhang, J., Lu, B., Huang, Z., & Ji, L. (2024) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2024.119163 · Cited by 3
Bhushan, S. R., & Kowdley, K. V. (2025) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000001109 · Cited by 3
Self-citationCheng, T., Li, H., Luo, X., Ju, L., Chen, L., Shao, J., She, Y.-J., Li, M., & Bian, Z. (2021) · Current Medical Science · doi:10.1007/s11596-021-2458-3 · Cited by 3
Classic Autoimmune Liver Disorders and Celiac Hepatitis
Amir, M., & Parekh, S. (2021) · Clinical Liver Disease · doi:10.1002/cld.1056 · Cited by 3
Gut Microbiota and Pancreatobiliary System
Ryu, K.-H. (2020) · Korean Journal of Gastroenterology · doi:10.4166/kjg.2020.75.5.231 · Cited by 4
“, New York City, NY, USA)와 같은 반(半)합성(semi-synthetic) 담즙산 들도 개발되어 원발성 담즙성 담관염(primary biliary cholangitis)에 대한 치료 요법으로 사용되고 있다.(59) 담즙산 조성”
Up-to-Date Snapshot of Current and Emerging Medical Therapies in Primary Biliary Cholangitis
Warsop, Z. I., Anand, N., Maliki, H. A., Souza, S. D., Kamyab, A. A., Hadad, A. A., & Alrubaiy, L. (2024) · Journal of Personalized Medicine · doi:10.3390/jpm14121133 · Cited by 4
“The POISE trial highlighted a dose-related statistically significant increase in pruritus incidence until 6 months, though, at 12 months, this significance was lost [51].”
InfluentialEditorial: The evolving paradigms and treatments for primary biliary cholangitis
Vuppalanchi, R., & Kowdley, K. V. (2023) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17779 · Cited by 5
Self-citationMacDonald, N., Loh, R., Fenkel, J. M., Sass, D. A., & Halegoua-DeMarzio, D. L. (2024) · BMC Gastroenterology · doi:10.1186/s12876-023-03108-4 · Cited by 3
“…received FDA approval in 2016 after the POISE trial showed that 46–47% of patients receiving the medication were able to achieve reduction in alkaline phosphatase to less than 1.67 times the upper limit of normal and normalization of bilirubin compared to 10% of patients in the placebo group [12].”
BackgroundInfluentialProgress and prospects of gut microbiota-targeted therapy for primary biliary cholangitis
Tang, X. R., & You, X. (2025) · Gut Pathogens · doi:10.1186/s13099-025-00753-w · Cited by 4
“%) are common adverse effects [8], with pruritus exhibiting dose dependency [9] (incidence was 56% in the 5-10 mg group, 68% in the 10 mg group and 58% in the placebo group [10]).”
A novel therapy for hepatic cholestasis treatment—the combination of rosiglitazone and fenofibrate
Chen, Y., Yang, S., Liu, L., Yang, X., Duan, Y., Zhang, S., & Han, J. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.175428 · Cited by 3
Drug treatments to prevent first decompensation in cirrhosis
Kezer, C. A., Berzigotti, A., Fortune, B. E., & Simonetto, D. A. (2024) · Hepatology · doi:10.1097/hep.0000000000001117 · Cited by 4
Buechter, M., Manka, P. P., Bulut, K., Gerken, G., & Kahraman, A. (2025) · Journal of Personalized Medicine · doi:10.3390/jpm15030079 · Cited by 5
“In addition, PPAR agonists, such as bezafi-brate and elafibranor, downregulate the expression of bile acid synthase CYP7A1, which is the key regulator of bile acid synthesis, thereby having beneficial effects on PBC in (pre)clinical trials [36,56,66].”
InfluentialPiccolo, P., Ferriero, R., Perna, C., Nusco, E., Monti, M., Cegli, R. D., Barbato, A., Sorrentino, N. C., Viscomi, M. T., Cariello, M., et al. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102593 · Cited by 4
“42,43 The present study unravels the potential of a new treatment for liver fibrosis based on delivery of the miR-34b/c.”
Nie, Y., Shi, Y., & Yang, Y. (2025) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2025.00212 · Cited by 8
A Short Review on Obeticholic Acid: An Effective Modulator of Farnesoid X Receptor
Narayanan, A. K., Sudhindran, S., Balakrishnan, D., Gopalakrishnan, U. A., Malick, S., Valsan, A., Philips, C. A., & Watson, C. J. E. (2023) · Current Clinical Pharmacology · doi:10.2174/0127724328239536230919070001 · Cited by 3
Feng, J., Wang, X., Ji, L., Liang, X., Liangpunsakul, S., Huang, L., Zhang, X., Gao, Y., Fang, M., Yu, Z., et al. (2025) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2025.120760 · Cited by 3
Bile acid metabolism and T cell responses in cholangiopathy: Not one-way traffic
Shetty, S., & Boyer, J. L. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.07.012 · Cited by 4
Therapeutics for Pruritus in Cholestatic Liver Disease: Many Treatments but Few Cures
Pederson, M., & Mayo, M. J. (2018) · Current Hepatology Reports · doi:10.1007/s11901-018-0397-7 · Cited by 3
Emerging drugs for the treatment of primary biliary cholangitis
Phaw, N. A., Dyson, J. K., & Jones, D. E. (2020) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2020.1751814 · Cited by 4
“The most common side-effect of the medication at both 12 month and 3-year follow-up assessment was pruritus, with approximately 56-68% and 77% of patients experiencing that symptom, respectively [13,14].”
BackgroundInfluentialSelf-citationStygar, D. M., Bogielski, B., Michalczyk, K., Skrzep-Poloczek, B., Suchocka, A., Nikiel, K., Kukla, K., Wasek, R., Staniszewski, J., Matyja, M., et al. (2026) · Frontiers in Physiology · doi:10.3389/fphys.2026.1788973 · Cited by 4
“For UDCA-non-responsive PBC patients, obeticholic acid (OCA), a potent farnesoid X receptor (FXR) agonist, offers a newer alternative that also modulates bile acid metabolism and exhibits anti-in fl ammatory and antioxidant properties (Nevens et al., 2016).”
Novel Therapies for Cholestatic Liver Disease.
Levy, C. (2019) · PubMed Central · Cited by 4
Zhang, Y., Fan, X., Song, B., Liu, Y., Chen, Y., Zheng, T., Guo, Y., Duan, T., Huang, Z., & Yang, L. (2023) · European Radiology · doi:10.1007/s00330-023-10080-w · Cited by 3
Labanca, S., Cacciato, V., Borro, P., Marenco, S., Pieri, G., Picciotto, A., Torres, M. C. P., & Giannini, E. G. (2021) · Immuno · doi:10.3390/immuno1040033 · Cited by 3
Magen-Darm-Mittel und Lebertherapeutika
Mössner, J. (2017) · Springer eBooks · doi:10.1007/978-3-662-54630-7_33 · Cited by 2
PPAR agonists for primary biliary cholangitis
Gossard, A. A., & Gores, G. J. (2017) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(17)30256-x · Cited by 2
Schnitzbauer, A. A., & Bechstein, W. O. (2017) · Transplant International · doi:10.1111/tri.12942 · Cited by 2
“A new kid on the block is obeticholic acid (OCA) which has been shown to have the potential to reduce cholestatic parameters in nonresponders to UDCA [10].”
BackgroundInfluentialBergasa, N. V. (2021) · Springer eBooks · doi:10.1007/978-1-4471-4715-2_3 · Cited by 5
Besci, Ö., Güler, M. Ç., Foss‐Freitas, M. C., & Oral, E. A. (2025) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2025.2574318 · Cited by 3
“Activation of FXRs reduces triglyceride and cholesterol levels, suppresses hepatic bile acid synthesis, improves insulin sensitivity, enhances lipid and glucose metabolism, upre-gulates bile acid transporters, and has been suggested to protect hepatocytes against bile acid toxicity [136,137].”
Cai, R., Liu, Z., Feng, Z., Qin, M., Li, J., Zhao, Q., & He, X. (2024) · Organ medicine. · doi:10.1002/orm2.8 · Cited by 2
Improving Primary Biliary Cholangitis Outcomes in the Evolving Landscape of Second‐Line Therapies
Scaravaglio, M., Ronca, V., Carbone, M., & Invernizzi, P. (2025) · Liver International · doi:10.1111/liv.70030 · Cited by 2
“The major safety concerns that emerged in the trial and post-approval studies were worsening of pruritus and the occurrence of severe liver injury in patients with decompensated cirrhosis [5, 8].”
InfluentialSelf-citationKeitel, V., Gertzen, C. G. W., Spomer, L., Gohlke, H., & Häussinger, D. (2020) · Wiley eBooks · doi:10.1002/9781119436812.ch24 · Cited by 2
Okumura, T., Kimura, T., Iwadare, T., Wakabayashi, S., Kobayashi, H., Yamashita, Y., Joshita, S., Komatsu, M., Tanaka, N., Matsumoto, A., et al. (2025) · Hepatology Research · doi:10.1111/hepr.70018 · Cited by 3
Tanaka, A., Leung, P. S. C., Bowlus, C. L., & Gershwin, M. E. (2020) · Springer eBooks · doi:10.1007/978-3-030-51709-0_22 · Cited by 2
Self-citationPruritus, Fatigue, Osteoporosis and Dyslipoproteinemia in Pbc Patients: A Clinician’s Perspective
Dražilová, S., Koky, T., Macej, M., Janíčko, M., Simkova, D., Tsedendamba, A., Комарова, С. Г., & Jarčuška, P. (2024) · Gastroenterology Insights · doi:10.3390/gastroent15020030 · Cited by 4
Novel preclinical developments of the primary sclerosing cholangitis treatment landscape
Sohal, A., & Kowdley, K. V. (2024) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2024.2330738 · Cited by 4
“Obeticholic acid is currently approved for the treatment for primary biliary cholangitis based on improvement in serum ALP [36].”
BackgroundSelf-citationEnsuring timely treatment of patients with primary biliary cholangitis
Marschall, H.-U. (2018) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(18)30177-8 · Cited by 2
Self-citationvan Erpecum, K. J., Portincasa, P., Henegouwen, G. P. V. B., & Moschetta, A. (2025) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2025.04.009 · Cited by 2
Self-citationSaito, Y., Chen, S., Ikemoto, T., Teraoku, H., Yamada, S., Morine, Y., & Shimada, M. (2025) · The Journal of Medical Investigation · doi:10.2152/jmi.72.54 · Cited by 2
Maxwell, M., Deng, Y., Chen, B., Silveira, M. G., Boyer, J. L., & Assis, D. N. (2026) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70574 · Cited by 3
Floreani, A. (2021) · Springer eBooks · doi:10.1007/978-3-030-65908-0_8 · Cited by 2
Self-citationNing, Y., Zhou, I. Y., Schaub, J. R., Rotile, N. J., Boice, A. T., Ay, İ., Turner, S., & Caravan, P. D. (2025) · Investigative Radiology · doi:10.1097/rli.0000000000001202 · Cited by 4
Moderne Therapie der primär biliären Cholangitis
Strassburg, C. P. (2017) · Der Internist · doi:10.1007/s00108-017-0347-4 · Cited by 3
“Unter einer initialen Behandlung mit 5mg OCA und einer Dosissteigerung auf 10mg bei fehlendem Erreichen des primären Studienendpunkts wurde in der Phase-III-Studie POISE in der Kombinationstherapie mit UDCA signifikant häufiger der primäre Endpunkt erreicht als unter Placebo (primärer Endpunkt: Senkung der AP unter de…”
BackgroundPrimary Biliary Cholangitis in 2025: A New Frontier
Klatzkow, H. R., Bhavsar‐Burke, I., Pearson, M. M., & Wentworth, B. J. (2025) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000003559 · Cited by 2
Prevalence and incidence of chronic kidney disease in patients with primary biliary cholangitis
Sousa, J. M., Rodríguez‐Tajes, S., Hernández‐Guerra, M., et al. (2026) · Journal of Gastroenterology · doi:10.1007/s00535-026-02442-0 · Cited by 2
“…prognosis, the introduction of ursodeoxycholic acid (UDCA) as first-line therapy, followed by second-line options such as obeticholic acid (OCA) [2] and fibrates [3], and more recently seladelpar [4] and elafi-branor [5], has significantly improved outcomes in patients who achieve a treatment…”
Melek, J., Staňková, P., Peterová, E., Maseko, T. E., Špalková, V., Matar, R., Ibrahim, A., Elkalaf, M., Podhola, M., Štefela, A., et al. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118542 · Cited by 3
Ahmad, A. M., Sanderson, K., Dickerson, D., & Adda, N. (2021) · International Journal of Gastroenterology · doi:10.11648/j.ijg.20210502.16 · Cited by 3
Bile Acids as Regulatory Signalling Molecules
Matz‐Soja, M. (2020) · Springer eBooks · doi:10.1007/978-3-030-39684-8_5 · Cited by 2
Validation of PBC‐10 in Japanese patients with primary biliary cholangitis
Takeuchi, A., Abe, M., Furukawa, S., Namisaki, T., Takahashi, A., Abe, K., Kikuchi, K., Miura, R., Tachizawa, N., Asaoka, Y., et al. (2025) · Hepatology Research · doi:10.1111/hepr.14199 · Cited by 3
“14 24 Previously, we created a Japanese version of the PBC - 40 using the back - translation method and validated it in a cohort of 180 Japanese patients with PBC. 25 Furthermore, from 2015 to 2016, we conducted a nationwide multicenter study to investigate HRQOL in 496 Japanese patients with PBC.…”
Proteomics in Primary Biliary Cholangitis
Li, Y., Tang, R., Leung, P. S. C., Gershwin, M. E., & Ma, X. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9420-5_11 · Cited by 2
Fatigue in Primary Biliary Cholangitis: No Place for Rituximab
Beuers, U. H., & Hohenester, S. D. (2019) · Hepatology · doi:10.1002/hep.30906 · Cited by 2
“(2) Potential second-line treatments are also available when UDCA alone is not effective enough: the farnesoid X receptor agonist obeticholic acid,(3) conditionally approved by North American (US Food and Drug Administration) and European (European Medicines Agency) authorities as a second-line treatment in PBC, or th…”
BackgroundSelf-citation彰, 本., Ikegami, T., & 靖司, 松. (2018) · 胆道 · doi:10.11210/tando.32.233 · Cited by 2
Editorial: scoring systems in primary biliary cholangitis – time to make a move
Mells, G. F., & Jones, D. E. (2017) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13984 · Cited by 2
“gress in the development of second-line therapies for high risk patients with this condition.(2) Accurate methods to risk-stratify PBC patients and identify those in need of second-line therapy are therefore required.”
BackgroundSelf-citationZimmer, V., & Lammert, F. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.12.008 · Cited by 2
“The changing and vital landscape of second-line options in PBC treatment is underscored by the recent conditional FDA licensing of obeticholic acid (OCA) as the first-in-class farnesoid X receptor (FXR) agonist, regulating BA synthesis and transport, after phase III randomized data (POISE trial) demonstrated biochemic…”
BackgroundDisease-modifying therapies and symptomatic management for primary biliary cholangitis
Patel, R., Portone, G., Lambert, J. A., Mak, S., & Alrubaiy, L. (2021) · British Journal of Hospital Medicine · doi:10.12968/hmed.2021.0247 · Cited by 3
Yoshida, E. M., Swain, M. G., Tsien, C. D., Tam, E., Bailey, R. J., Grbic, D., Ko, H. H., Ramji, A. S., Hilzenrat, N., Elkhashab, M., et al. (2022) · Canadian Liver Journal · doi:10.3138/canlivj-2021-0038 · Cited by 4
New therapeutic perspectives in non-alcoholic steatohepatitis
Ampuero, J., Sanchez-Torrijos, Y. M., Aguilera, V., Bellido, F., & Romero‐Gómez, M. (2018) · Gastroenterología y Hepatología (English Edition) · doi:10.1016/j.gastre.2017.07.016 · Cited by 7
Recent Advances in Primary Biliary Cholangitis Treatment
Das, T. S., & Vuppalanchi, R. (2025) · Clinics in Liver Disease · doi:10.1016/j.cld.2025.06.008 · Cited by 3
Wang, W.-T., Tian, J.-R., Gao, S., Wang, M.-B., Luo, Y., & Li, X. (2026) · Metabolites · doi:10.3390/metabo16020092 · Cited by 2
“Application in PBC: Obeticholic acid has been approved by the FDA for patients with PBC who inadequately respond to ursodeoxycholic acid, with effects including improvement in cholestasis and alleviation of pruritus [85].”
Pathophysiologic Basis for Alternative Therapies for Cholestasis
Fuchs, C. D., Halilbasic, E., & Trauner, M. (2020) · Wiley eBooks · doi:10.1002/9781119436812.ch30 · Cited by 2
Self-citationColangitis biliar primaria: caracterización de una cohorte retrospectiva
Ayala-Sierra, E. F., Maya, O. G. M., Guerrero-Pérez, F., & Cardona-Jaramillo, M. (2022) · Hepatología · doi:10.52784/27112330.159 · Cited by 2
Liu, B. D. X., & Qureshi, K. (2022) · Digestive Diseases and Sciences · doi:10.1007/s10620-022-07661-y · Cited by 2
“Patients receiving OCA (46%) achieved this outcome significantly more frequently than the placebo group (10%) [8].”
BackgroundPratt, D. S. (2019) · Hepatology · doi:10.1002/hep.30517 · Cited by 2
Practical management of primary biliary cholangitis
Parés, A. R. (2021) · Revista Española de Enfermedades Digestivas · doi:10.17235/reed.2021.8219/2021 · Cited by 3
Adverse events associated with obeticholic acid: a real-world, pharmacovigilance study
Zhang, C., & Wang, J. (2025) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2025.2487144 · Cited by 2
He, Q., Jiang, M., Wang, Y., & Zheng, T. (2025) · British Journal of Clinical Pharmacology · doi:10.1002/bcp.70186 · Cited by 3
“17,39 Most pruritus occurred within the first month of treat-ment and tended to resolve gradually with continued dosing.”
Progressive Familial Intrahepatic Cholestasis
Khanna, R., & Gautam, V. (2022) · Annals of Pediatric Gastroenterology & Hepatology · doi:10.5005/jp-journals-11009-0053 · Cited by 2
Tsujikawa, M., Shiozaki, T., Kaikawa, Y., et al. (2015) · INFM-OAR (INFN Catania) · doi:10.5281/zenodo.37168 · Cited by 1
Gerussi, A., & Fornai, M. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108144 · Cited by 2
New Onset of Ecchymosis Following Initiation of Obeticholic Acid
Ma, M., & Weisberg, I. S. (2017) · The American Journal of Gastroenterology · doi:10.14309/00000434-201710001-01362 · Cited by 1
Bile acid signaling: from dynamic pool composition to inter-organ communication
Yang, F., Wei, T., Liu, K. L., Chu, H., & Yang, L. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1890710 · Cited by 2
“…phase 3 trial demonstrated that obeticholic acid markedly ameliorated cholestatic biochemical parameters in PBC patients with suboptimal response or intolerance to UDCA, yet the drug was associated with a higher rate of adverse events including pruritus and increased LDL-C versus placebo (135).”
Primary Sclerosing Cholangitis
Bergasa, N. V. (2021) · Springer eBooks · doi:10.1007/978-1-4471-4715-2_5 · Cited by 1
Mells, G. F. (2023) · Medicine · doi:10.1016/j.mpmed.2023.03.004 · Cited by 1
Design, synthesis, and biological evaluation of novel FXR agonists based on auraptene
Qiu, Q., Wang, Y., Gu, G., Fan, Y., Zhang, S., Zhao, Y., & Ling, B. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.105198 · Cited by 1
Bile Acids and the Metabolic Disorders
Roh, J. H., & Yoon, J.-H. (2018) · Korean Journal of Clinical Pharmacy · doi:10.24304/kjcp.2018.28.4.273 · Cited by 1
Ruiu, A., Calabrese, M. P., Meschisi, P., Plebani, R., Maria, B., Lleò, A., & Ronca, V. (2026) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2026.106883 · Cited by 1
Primär biliäre Cholangitis – etablierte und neue Therapien
Vetter, M., & Kremer, A. E. (2018) · Der Internist · doi:10.1007/s00108-018-0427-0 · Cited by 1
Seladelpar: New hope for patients with primary biliary cholangitis
Nevzorova, Y. A., & Cubero, F. J. (2024) · Med · doi:10.1016/j.medj.2024.03.019 · Cited by 1
Primary Biliary Cholangitis (Formerly Primary Biliary Cirrhosis)
Trivedi, P. J., & Hirschfield, G. M. (2019) · Wiley eBooks · doi:10.1002/9781119211419.ch38 · Cited by 1
Self-citationBeattieR.H.Sturrock, JenniferK.Rogers, RossSadler, BerneFerry, Roberts, C. A., RogerW.Chapman, & Lynch, K. D. (2018) · Journal of Gastroenterology and Hepatology Research · doi:10.17554/j.issn.2224-3992.2018.07.797 · Cited by 2
Fuzheng Huayu formula ameliorates chronic cholestatic liver injury by upregulating PPARa in mice
Zhang, Z., Tang, E.-Q., Li, C., Wang, B., Liang, Y., Lv, J.-X., Chen, G., Liu, W., Mu, Y.-P., Liu, P., et al. (2026) · Chinese Medicine · doi:10.1186/s13020-026-01368-2 · Cited by 2
“Ursodeoxycholic acid therapy significantly improves outcomes and prolongs transplant-free survival in PBC patients [3], but with problems such as incomplete response, and heavy economic burden [4, 5].”
Dupas, J., Ho, N. F. H., & Hofmann, A. F. (2018) · Lipids · doi:10.1002/lipd.12052 · Cited by 1
Effective medical treatments for PSC needed ASAP - is AESOP the answer?
Trauner, M. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.05.009 · Cited by 1
Self-citationPerez, C. F. M., Gulamhusein, A. F., Carbone, M., Trivedi, P. J., van der Meer, A. J., Corpechot, C., Battezzati, P. M., Lammers, W. J., Cazzagon, N., Floreani, A., et al. (2020) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000002029 · Cited by 5
Self-citationPrimary Biliary Cholangitis: Updates in Management and Goals of Treatment
Carlson, K., Salge, M. H., & Cholankeril, G. T. (2024) · Current Hepatology Reports · doi:10.1007/s11901-024-00667-2 · Cited by 1
Tanaka, A., & Gershwin, M. E. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-812102-3.00058-0 · Cited by 2
Jiang, Y., Li, S., Paudel, D., Tan, M., & Zhang, B. (2026) · Sleep research. · doi:10.1002/slp2.70032 · Cited by 1
“60,61 This would not only provide novel therapeutic strategies but also serve as a touchstone for validating the hypothesis that BAs drive sleep disorders.”
Kugiyama, Y., Abe, M., Namisaki, T., Yoshiji, H., Abe, K., Ohira, H., Shirahashi, R., Yokoyama, K., Fukunaga, A., Kawata, K., et al. (2025) · Hepatology Research · doi:10.1111/hepr.70035 · Cited by 1
Role of liver sinusoidal endothelial cells in the diagnosis and treatment of liver diseases
Fernández‐Iglesias, A., & Gracia‐Sancho, J. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95262-0.00023-1 · Cited by 1
[Apolipoprotein B and small, dense LDL-C].
Ito, Y. (2012) · PubMed · Cited by 1
Rigopoulou, E. I. (2020) · Springer eBooks · doi:10.1007/978-3-030-24432-3_24 · Cited by 1
Cholangite biliaire primitive : mise à jour
Barbosa, J. V., Vionnet, J., Sciarra, A., Sempoux, C. L., Aubert, V., Moradpour, D., & Christinet, M. F. (2018) · JMIG · doi:10.53738/revmed.2018.14.616.1489 · Cited by 3
Feng, C. (2018) · Digestive Diseases and Sciences · doi:10.1007/s10620-018-5083-7 · Cited by 1
“Ocaliva® is not indicated as a monotherapy substitute for UDCA except in the event of UDCA intolerance; it is only in this setting that a 3-month washout was used in the registrational study [3].”
MethodWebb, G. J., & Hirschfield, G. M. (2018) · Clinics in Liver Disease · doi:10.1016/j.cld.2018.03.004 · Cited by 2
Self-citation
Metadata
- Authors
- Nevens, F., Andreone, P., Mazzella, G., Strasser, S. I., Bowlus, C., Invernizzi, P., Drenth, J. P. H., Pockros, P. J., Regula, J., Beuers, U., Trauner, M., Jones, D. E., Floreani, A., Hohenester, S., Luketic, V., Shiffman, M., van Erpecum, K. J., Vargas, V., Vincent, C., Hirschfield, G. M., Shah, H., Hansen, B., Lindor, K. D., Marschall, H.-U., Kowdley, K. V., Hooshmand-Rad, R., Marmon, T., Sheeron, S., Pencek, R., MacConell, L., Pruzanski, M., & Shapiro, D.
- Affiliations
- University of Padua (IT)
- Humanitas University (IT)
- University Health Network (CA)
- ORCID
- Nevens, Frederik
- Mazzella, Giuseppe
- Strasser, Simone I.
- Bowlus, Christopher
- Invernizzi, Pietro
- Drenth, Joost P.H.
- Pockros, Paul J.
- Beuers, Ulrich
- Trauner, Michael
- Jones, David E.
- Floreani, Annarosa
- Hohenester, Simon
- Luketic, Velimir
- Shiffman, Mitchell
- Vincent, Catherine
- Hirschfield, Gideon M.
- Shah, Hemant
- Hansen, Bettina
- Lindor, Keith D.
- Marschall, Hanns-Ulrich
- Kowdley, Kris V.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-08-18
- Volume
- 375
- Issue
- 7
- Pages
- 631-643
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2518389324
- Cited by
- 1,131
- References
- 33
- Citations by year
- 2026: 91 · 2025: 118 · 2024: 108 · 2023: 100 · 2022: 123 · 2021: 115 · 2020: 123 · 2019: 111 · 2018: 129 · 2017: 97 · 2016: 14
- FWCI
- 84.82
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- RePub (Erasmus University Rotterdam) (submittedVersion, other-oa)
- BOA (University of Milano-Bicocca) (submittedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- Utrecht University Repository (Utrecht University) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Lirias (submittedVersion)
- Pure Amsterdam UMC (submittedVersion, other-oa)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion, other-oa)
- Radboud Repository (Radboud University) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Utrecht University Repository (Utrecht University) (submittedVersion, other-oa)
- Funders
- Intercept Pharmaceuticals
- National Institute for Health and Care Research (NF-SI-0513-10091)
- Medical Research Council (MR/L001489/1)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
- Keywords
- obeticholic acid, primary biliary cirrhosis, farnesoid X receptor agonist, ursodeoxycholic acid, alkaline phosphatase, total bilirubin, liver fibrosis, pruritus, liver transplantation, liver cirrhosis, drug safety, dose comparison, noninvasive fibrosis assessment
- MeSH terms
- Adult, Aged, Alkaline Phosphatase, Bile Acids and Salts, Chenodeoxycholic Acid, Double-Blind Method, Female, Fibroblast Growth Factors, Humans, Liver Cirrhosis, Liver Cirrhosis, Biliary, Male, Middle Aged, Pruritus, Bone Density
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-12, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-12 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.